Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 132
3 152
2 52
1 25
NEB 4
Curative setting
A 54
C 2
NEB 4
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 37
Endocrine Tumours 21
Gastrointestinal Cancers 73
Genitourinary Cancers 70
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Sarcoma 12
Skin Cancers 29
Thoracic Malignancies 83
TMB-H solid tumours 1
Tumour agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 3
Skin Cancers 14
Thoracic Malignancies 11
TMB-H solid tumours 0
Tumour agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Osimertinib - Placebo Adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations ADAURA
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR exon 19 deletions or exon 21 (L858R) mutation ADAURA

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Margetuximab ChT Trastuzumab plus ChT Treatment of adult patients who have received two or more prior anti-HER2 regimes, at least one of which was for metastatic disease SOPHIA
    Breast Cancer
    		 Breast Cancer HER2+ SOPHIA

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Trastuzumab deruxtecan - ChT (irinitecan or paclitaxel) Treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma in patients who have received a prior trastuzumab-based regimen DESTINY-Gastric01
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma HER2+ DESTINY-Gastric01

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Trabectedin - Dacarbazine Treatment for patients with advanced soft-issue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients
    Sarcoma
    		 Soft tissue - Liposarcoma or leiomyosarcoma - -

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Niraparib - Placebo Maintenance treatment for patients with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based ChT PRIMA/ENGOT-OV26/COG-3012
    Gynaecological Malignancies
    		 Ovarian, fallopian tubes and peritoneum cancer HRD+ PRIMA/ENGOT-OV26/COG-3012

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Olaparib Bevacizumab Placebo + bevacizumab Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability PAOLA-1
    Gynaecological Malignancies
    		 High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer BRCA-mut PAOLA-1

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Olaparib Bevacizumab Placebo + bevacizumab Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability PAOLA-1
    Gynaecological Malignancies
    		 High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer HRD+, BRCA-WT PAOLA-1

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Avelumab - Single arm Adult patients with metastatic Merkel cell carcinoma (MCC) JAVELIN Merkel 200 (Part A - pretreated patients)
    Skin Cancers
    		 Merkel cell carcinoma - JAVELIN Merkel 200 (Part A - pretreated patients)

    4

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      4
    Nivolumab + ipilimumab - ChT with cisplatin or carboplatin plus pemetrexed First-line treatment of adult patients with unresectable malignant pleural mesothelioma. CheckMate743
    Thoracic Malignancies
    		 Pleural mesothelioma - CheckMate743

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Nivolumab + ipilimumab - Single arm Patients with HCC who have been previously treated with sorafenib CheckMate 040
    Gastrointestinal Cancers
    		 Hepatobiliary Cancers - Hepatocellular Carcinoma - CheckMate 040

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Tazemetostat - Single arm (Phase II) Treatment for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection EZH-202
    Sarcoma
    		 Epithelioid INI1-negative EZH-202

    1

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      1
    Tepotinib - Single arm For adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. VISION
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer METex14 skipping VISION

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Cemiplimab - Platinum based ChT (Crossover allowed) First-line locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC EMPOWER-Lung 1
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1>50% negative EGFR, ALK or ROS1 EMPOWER-Lung 1

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Cabozantinib - Sunitinib First-line treatment of adult patients with intermediate or poor risk advanced RCC CABOSUN
    Genitourinary Cancers
    		 Renal cell cancer - CABOSUN

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Dostarlimab - Single arm Treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that have progressed on or following prior treatment with a platinum-containing regimen GARNET
    Gynaecological Malignancies
    		 Endometrial Cancer dMMR or MSI-H GARNET

    3

    PRELIMINARY SCORE

    • ORR

    ADJUSTMENTS

    SCORE

    • F3
      3
    Nivolumab + ipilimumab 2 cycles of platinum-based ChT Chemotherapy First line treatment of mNSCLC with no sensitising EGFR mutation or ALK translocation CheckMate-9LA
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - CheckMate-9LA

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    5-FU/LV (fluorouracil + leucovorin) - Lomustine (MeCCNU) + vincristine + 5-FU Patients with Dukes' stage B and C colon cancer NSABP C-03
    Gastrointestinal Cancers
    		 Colon Cancer - NSABP C-03

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5-FU (fluorouracil) Folinic acid Observation Patients with surgically resected colon cancer in Dukes' stage C
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5-FU/LV (fluorouracil + leucovorin) - Observation High-risk stage II or stage III colon cancer NCCTG 874651
    Gastrointestinal Cancers
    		 Colon Cancer - NCCTG 874651

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5-FU (fluorouracil) Folinic acid Surgery alone Patients with resectable Dukes B and C (AJCC/UICC Stage II and Stage III) colon carcinoma GIVIO-SITAC 01
    Gastrointestinal Cancers
    		 Colon Cancer - GIVIO-SITAC 01

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Meta-analysis) Patients with stage II and III colon cancer (ITT and age stratified including >70 years)
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Pooled-analysis) Patients with stage II and III colon cancer
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Meta-analysis) Patients with resected stage II and III colon cancer
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5-FU/LV (fluorouracil + leucovorin) or 5-FU/LEV (fluorouracil + levamisole) - Surgery alone (Meta-analysis) Patients with resected stage II and III colon cancer
    Gastrointestinal Cancers
    		 Colon Cancer - -

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5FU/LEV (5-fluorouracil + levamisole) - Levamisole Resected stage III (Dukes stage C) colon cancer Intergroup 0035
    Gastrointestinal Cancers
    		 Colon Cancer - Intergroup 0035

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Tivozanib - Sorafenib Adult patients with relapsed or refractory advanced RCC following ≥2 prior systemic therapies TIVO-3
    Genitourinary Cancers
    		 Renal cell cancer - TIVO-3

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Enzalutamide ADT (androgen deprivation therapy) Placebo + ADT For the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy ARCHES
    Genitourinary Cancers
    		 Prostate cancer - ARCHES

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Lorlatinib - Crizotinib Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive (NSCLC) previously not treated with an ALK inhibitor CROWN
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ CROWN

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Sacituzumab govitecan - Physician’s choice of single agent ChT Treatment of patients with unresectable or metastatic TNBC who have received ≥2 prior systemic therapies, ≥1 of them for advanced disease ASCENT
    Breast Cancer
    		 Breast Cancer Triple-negative ASCENT

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Nivolumab Cabozantinib Sunitinib First-line treatment of adult patients with advanced RCC CheckMate-9ER
    Genitourinary Cancers
    		 Renal cell cancer - CheckMate-9ER

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.